Mirati Therapeutics, INC. (NASDAQ:MRTX) Files An 8-K Results of Operations and Financial Condition

On November 1, 2017, Mirati Therapeutics, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2017.A copy of this press release is attached hereto as Exhibit99.1.

The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

(d) Exhibits.

Mirati Therapeutics, Inc. ExhibitEX-99.1 2 ex991-q317earningsrelease.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 MIRATI THERAPEUTICS REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS    SAN DIEGO - November 1,…To view the full exhibit click here